Altered irinotecan metabolism in a patient receiving phenytoin.
The systemic exposure to the anticancer agent irinotecan (CPT-11) and its active metabolite SN-38 were 79 and 92% reduced, respectively, relative to literature data, by concomitant phenytoin therapy. This finding suggests that increased doses of CPT-11 should be given to patients treated simultaneously with these drugs, to achieve adequate levels of SN-38.
Mathijssen
Ron H J
RH
Rotterdam Cancer Institute, Daniel den Hoed Kliniek, Department of Medical Oncology, 3075 EA Rotterdam, The Netherlands. mathijssen@onch.azr.nl
Sparreboom
Alex
A
Dumez
Herlinde
H
van Oosterom
Allan T
AT
de Bruijn
Ernst A
EA
D000328:Adult; D000927:Anticonvulsants / Q000494:pharmacology; D000972:Antineoplastic Agents, Phytogenic / Q000493:pharmacokinetics* / Q000627:therapeutic use*; D001932:Brain Neoplasms / Q000188:drug therapy* / Q000378:metabolism; D002166:Camptothecin / Q000031:analogs & derivatives / Q000493:pharmacokinetics* / Q000627:therapeutic use*; D004347:Drug Interactions; D005910:Glioma / Q000188:drug therapy* / Q000378:metabolism; D006801:Humans; D000077146:Irinotecan; D010672:Phenytoin / Q000494:pharmacology*; D059004:Topoisomerase I Inhibitors
D000927:Anticonvulsants; D000972:Antineoplastic Agents, Phytogenic; D059004:Topoisomerase I Inhibitors; D010672:Phenytoin; D000077146:Irinotecan; D002166:Camptothecin